Analysts See $1.21 EPS for ANI Pharmaceuticals, Inc. (ANIP)

July 11, 2018 - By Linda Rogers

Investors sentiment increased to 1.43 in Q1 2018. Its up 0.34, from 1.09 in 2017Q4. It increased, as 12 investors sold ANI Pharmaceuticals, Inc. shares while 42 reduced holdings. 37 funds opened positions while 40 raised stakes. 6.72 million shares or 7.48% more from 6.25 million shares in 2017Q4 were reported.
Aperio Group Incorporated Limited Liability Corp holds 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 4,780 shares. Avalon Advisors Ltd Liability Company has 44,119 shares for 0.08% of their portfolio. 5,918 are held by Sg Americas Securities Ltd Liability Corp. Gsa Capital Partners Limited Liability Partnership invested in 0.02% or 7,100 shares. Ranger Invest Mgmt Lp accumulated 0.21% or 49,217 shares. Bogle Invest Limited Partnership De has 42,700 shares. Perkins Capital Management reported 1.42% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Mark Sheptoff Financial Planning Ltd Liability accumulated 0.16% or 4,050 shares. Daiwa Securities Grp Inc holds 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 64 shares. Cwm Limited Liability Corp has 5 shares for 0% of their portfolio. Strs Ohio holds 10,400 shares or 0% of its portfolio. The Japan-based Nomura Hldg Incorporated has invested 0.03% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Moreover, Proshare Advsr Ltd Liability has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) for 6,689 shares. Alphamark Advisors Ltd reported 4,200 shares. Cubist Systematic Strategies Limited Liability Com holds 0.06% or 18,027 shares in its portfolio.

Since March 1, 2018, it had 0 insider buys, and 10 selling transactions for $18.16 million activity. PRZYBYL ARTHUR also sold $1.47 million worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares. The insider Marken James G. sold $258,640. The insider RAYNOR DANIEL sold 7,215 shares worth $439,047. MARSHBANKS TRACY also sold $120,647 worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares.

Analysts expect ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to report $1.21 EPS on August, 2.They anticipate $0.33 EPS change or 37.50 % from last quarter’s $0.88 EPS. ANIP’s profit would be $14.26 million giving it 14.70 P/E if the $1.21 EPS is correct. After having $1.23 EPS previously, ANI Pharmaceuticals, Inc.’s analysts see -1.63 % EPS growth. The stock decreased 0.01% or $0.01 during the last trading session, reaching $71.15. About 91,435 shares traded or 18.99% up from the average. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 31.37% since July 12, 2017 and is uptrending. It has outperformed by 18.80% the S&P500.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Ratings Coverage

Among 2 analysts covering ANI Pharmaceuticals (NASDAQ:ANIP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ANI Pharmaceuticals had 2 analyst reports since February 28, 2018 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Wednesday, February 28 with “Buy”. Cantor Fitzgerald initiated the stock with “Buy” rating in Monday, June 11 report.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $838.60 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It has a 35575 P/E ratio. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

More important recent ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) news were published by: which released: “4 Undervalued MedTech Stocks to Consider Amid Volatility” on June 19, 2018, also published article titled: “ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP”, published: “Premarket analyst action – healthcare” on June 12, 2018. More interesting news about ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was released by: and their article: “Market Trends Toward New Normal in EnviroStar, Rowan Companies, Del Taco Restaurants, ANI Pharmaceuticals …” with publication date: June 25, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.